Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Efficacy and Safety of Levetiracetam in the Prophylaxis of Migraine Headaches in Children - a Randomised Trial Publisher



Ghazavi M1 ; Jelodar G1, 2 ; Yaghini O1 ; Nasiri J1 ; Sadeghian S2 ; Malamiri RA2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Paediatric Neurology and Child Growth and Development Centre, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Paediatric Neurology, Golestan Medical, Educational, and Research Centre, Ahvaz Jundishapur University of Medical Sciences, #90, Golestan Blvd., Ahvaz, 6135733118, Iran

Source: Pediatria Polska Published:2019


Abstract

Introduction: Migraine headaches have a negative impact on daily living activities in children. Many children with migraine need prophylactic medications in addition to biobehavioural measures. Until now, only topiramate has been approved by the FDA (US Food and Drug Administration) as a prophylactic medication in children with migraine. However, topiramate has many unacceptable adverse cognitive effects, therefore, conducting well-designed trials to show the efficacy of safer medications has been recommended. Aim of the study: We conducted a trial to assess the efficacy and safety of levetiracetam in the prophylaxis of migraine headaches in children. Material and methods: In an open-label, randomised, controlled trial, we assessed the efficacy and safety of levetiracetam in the prophylaxis of migraine headaches in children compared to a well-known prophylactic agent, amitriptyline. The primary outcome measure was reduction of monthly headache frequency. The secondary outcome measures were reduction in headache duration and severity. In addition, we studied the effect of these medications on headache disability score using the Paediatric Migraine Disability Assessment (PedMIDAS) questionnaire, as well as their adverse side effects. The trial was continued for three months after administering the medications. Results: We enrolled 66 children with migraine, and 60 of them completed the study (30 in each arm). Ninety per cent (27/30) of children in each arm showed more than 50% reduction in monthly headache frequency. Duration and severity of headaches were also significantly decreased at the end of the trial. In addition, the safety profile of medications was acceptable, and headache disability score was significantly improved at the end of the trial. Conclusions: These results indicate that levetiracetam might be effective and safe in the prophylaxis of migraine headaches in children. It deserves to be considered in the prophylaxis of migraine headaches in children. © 2019 Termedia Publishing House Ltd.. All rights reserved.
Other Related Docs
36. Topiramate and the Vision: A Systematic Review, Clinical Ophthalmology (2012)
45. The Preventive Role of Topical Timolol in Treatment of Migraine Headaches, Journal of Research in Medical Sciences (2005)